Mixed results for Recentin in mCRC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Recentin cediranib met one co-primary endpoint but missed the other in the Phase III HORIZON II trial to treat metastatic colorectal cancer (mCRC). Recentin plus FOLFOX or XELOX significantly improved progression-free survival (PFS) vs. placebo plus FOLFOX or XELOX, but did not significantly improve overall survival.

In March, the pharma reported that Recentin plus FOLFOX missed the primary endpoint of non-inferiority to Avastin bevacizumab plus FOLFOX in PFS in the Phase II/III HORIZON III trial for the indication. Based on the results from the two trials, AstraZeneca said it does not intend to submit regulatory applications for first-line mCRC (See BioCentury, March 15, 2010). ...